The company’s project portfolio is a blend of small, orally active immunomodulatory molecules

The company’s project portfolio is a blend of small, orally active immunomodulatory molecules and antibody-based immunotherapy. These projects are strategically focused on conditions where the immune system’s function is central to disease progression or resolution. By harnessing the power of the immune system, Active Biotech aims to provide targeted treatments for challenging conditions, such as hematological malignancies and inflammatory diseases. One of Active Biotech’s most advanced projects is Tasquinimod, which is being developed as a treatment for hematological malignancies. Currently in clinical phase Ib/IIa, Tasquinimod is specifically being studied for its efficacy in treating myelofibrosis and multiple myeloma. This drug is designed to modulate the immune system and offer a potential therapeutic approach for cancers where traditional treatments have shown limited success.